{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:28:33Z","timestamp":1794634113777,"version":"4.9.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first authors to report a case of Hodgkin lymphoma in a psoriatic patient receiving ustekinumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 22-year-old asymptomatic female patient presented to our department to investigate an enlarged cervical lymph node. Her past history was unremarkable, except for psoriasis since age 13. Two months before presentation the decision to administer Ustekinumab was taken and the patient had already received 3 doses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>During workup a Stage IV Hodgkin lymphoma was discovered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Ustekinumab administration was discontinued. The patient received treatment with the ABVD regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient's disease was refractory to the above-mentioned treatment. Therefore, a more aggressive regimen (BEACOPP escalated) was administered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Growing postmarketing surveillance data and case reports indicate that further research is warranted in order to elucidate a potential association between Ustekinumab and malignancy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020048","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T03:21:43Z","timestamp":1590636103000},"page":"e20048","source":"Crossref","is-referenced-by-count":5,"title":["A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis"],"prefix":"10.1097","volume":"99","author":[{"given":"Emmanouil","family":"Charakopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Spyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora-Athina","family":"Viniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nefeli","family":"Giannakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevastianos","family":"Hatzidavid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis Theodorou","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"R2-20240521","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/ced.12390","article-title":"Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis","volume":"39","author":"Meng","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"R3-20240521","first-page":"11","article-title":"Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis","volume":"5","author":"Krulig","year":"2010","journal-title":"Core Evid"},{"key":"R4-20240521","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0001-7310(12)70007-8","article-title":"Ustekinumab. Neoplasias y otros aspectos de seguridad","volume":"103","author":"Santos-Juanes","year":"2012","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"R5-20240521","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000366499","article-title":"Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis","volume":"230","author":"Puig","year":"2015","journal-title":"Dermatology"},{"key":"R6-20240521","doi-asserted-by":"crossref","first-page":"e12476","DOI":"10.1111\/dth.12476","article-title":"Risk of malignancy in psoriatic patients: our clinical experience","volume":"30","author":"Magnano","year":"2017","journal-title":"Dermatol Ther"},{"key":"R7-20240521","doi-asserted-by":"crossref","first-page":"e12508","DOI":"10.1111\/dth.12508","article-title":"Systemic treatment for psoriasis and malignancies: a real risk?","volume":"30","author":"Napolitano","year":"2017","journal-title":"Dermatol ther"},{"key":"R8-20240521","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R9-20240521","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"R10-20240521","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"R11-20240521","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1111\/jdv.13658","article-title":"Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre","volume":"31","author":"Vergou","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-20240521","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1440-0960.2011.00853.x","article-title":"The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis","volume":"53","author":"Young","year":"2012","journal-title":"Australas J Dermatol"},{"key":"R13-20240521","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00105-012-2526-5","article-title":"CD30-positives anaplastisch gro\u00dfzelliges T-zell-lymphom unter immunsuppressiver therapie einer pityriasis rubra pilaris mit ustekinumab","volume":"64","author":"Humme","year":"2013","journal-title":"Hautarzt"},{"key":"R14-20240521","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1002\/ibd.21877","article-title":"Malignant melanoma during ustekinumab therapy of Crohn's disease","volume":"18","author":"Ehmann","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R15-20240521","first-page":"326","article-title":"Gastric mucosa-associated lymphoid tissue lymphoma in a patient with severe psoriasis receiving ustekinumab","volume":"106","author":"Gonzalez-Ramos","year":"2015","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"R16-20240521","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1684\/ejd.2013.2096","article-title":"Multiple myeloma in a patient under ustekinumab\u2013are they related?","volume":"23","author":"Pinto-Almeida","year":"2013","journal-title":"Eur J Dermatol"},{"key":"R18-20240521","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/1744666X.2014.878649","article-title":"Ustekinumab for the treatment of psoriatic arthritis","volume":"10","author":"Wofford","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"R19-20240521","first-page":"123","article-title":"Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis","volume":"6","author":"Koutruba","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"R20-20240521","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2008.00628.x","article-title":"Th17 cells in human disease","volume":"223","author":"Tesmer","year":"2008","journal-title":"Immunol Rev"},{"key":"R22-20240521","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"R23-20240521","first-page":"202","article-title":"Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients","volume":"18","year":"2009","journal-title":"Prescrire Int"},{"key":"R24-20240521","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R25-20240521","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"R27-20240521","first-page":"301","article-title":"Efalizumab in the treatment of psoriasis","volume":"1","author":"Boehncke","year":"2007","journal-title":"Biologics"},{"key":"R28-20240521","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sder.2010.01.001","article-title":"Assessing long-term drug safety: lessons (re) learned from raptiva","volume":"29","author":"Seminara","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"R29-20240521","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.14068","article-title":"Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States","volume":"173","author":"Kimball","year":"2015","journal-title":"Br J Dermatol"},{"key":"R30-20240521","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/sj.jid.5700410","article-title":"The risk of lymphoma in patients with psoriasis","volume":"126","author":"Gelfand","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R31-20240521","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1365-2133.1999.02655.x","article-title":"Malignant tumours and psoriasis: a follow-up study","volume":"140","author":"Frentz","year":"1999","journal-title":"Br J Dermatol"},{"key":"R32-20240521","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1365-4632.2011.05310.x","article-title":"The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study","volume":"51","author":"Lee","year":"2012","journal-title":"Int J Dermatol"},{"key":"R33-20240521","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The risk of melanoma and hematologic cancers in patients with psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R34-20240521","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"},{"key":"R35-20240521","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J Invest Dermatol"},{"key":"R36-20240521","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/jid.2009.113","article-title":"Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis","volume":"129","author":"Brauchli","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R37-20240521","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjd.12744","article-title":"Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005-09","volume":"170","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"R38-20240521","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R39-20240521","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1523-1747.2000.00898.x","article-title":"Psoriasis, its treatment, and cancer in a cohort of Finnish patients","volume":"114","author":"Hannuksela-Svahn","year":"2000","journal-title":"J Invest Dermatol"},{"key":"R40-20240521","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jaad.2016.05.021","article-title":"Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: a population-based cohort study","volume":"75","author":"Dai","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R41-20240521","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/jdv.13619","article-title":"Skin cancer in patients with psoriasis","volume":"30","author":"Egeberg","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R42-20240521","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jaad.2010.04.046","article-title":"The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan","volume":"65","author":"Chen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R43-20240521","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"},{"key":"R44-20240521","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/sj.bjc.6605027","article-title":"Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden","volume":"100","author":"Ji","year":"2009","journal-title":"Br J Cancer"},{"key":"R45-20240521","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaad.2017.03.044","article-title":"The risk of malignancy among biologic-naive pediatric psoriasis patients: a retrospective cohort study in a US claims database","volume":"77","author":"Gu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R46-20240521","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R48-20240521","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1111\/bjd.15752","article-title":"Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database","volume":"177","author":"Florek","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T20:05:30Z","timestamp":1716321930000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":43,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020048","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}